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Abstract 
Many potentially valuable drugs, including protein kinase inhibitors (PKI), risk being dropped from further 
development, without exploration of their clinical benefits, if early studies show these drugs to inhibit hERG 
channel and therefore, to have a potential for prolonging ventricular repolarisation (QT interval). This QT-
phobia results from a perceived possibility of the clinical risks of QT-related ventricular proarrhythmia, further 
aggravated by uncertainties surrounding the regulatory evaluation of the risk and either approvability or 
restrictive labelling of the drug concerned. In reality, QT interval prolongation per se is only an imperfect 
surrogate of the proarrhythmia risk which is much smaller than perceived and compared to their other 
cardiovascular and non-cardiovascular risks. PKI-induced clinical hepatotoxicity, also evaluated on the basis of 
surrogate markers (serum transaminases and bilirubin) is another risk that far exceeds any risk arising from PKI-
induced QT interval prolongation. This review of the currently approved 28 PKIs places the QT-phobia 
surrounding the development of PKIs in its perspective by juxta-positioning their potential to induce ventricular 
dysfunction, arterial thrombotic events and hepatotoxicity. Available evidence suggests that hERG channel may 
prove to be a valuable therapeutic target in oncology. Therefore, the development, approval and labelling of 
such vital oncology drugs requires careful assessment of their benefits and their risk/benefit generally, without 
being overtly consumed by their potential QT-liability, in terms of their more direct consequences on clinically 
relevant endpoints of morbidity, mortality and quality of life. 
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Introduction 
Treatment of various cancers has been significantly revolutionized by the development of small 
molecule protein kinase inhibitors (PKIs), a vast majority of them in current clinical use being tyrosine 
kinase inhibitors. The perceived benefits of these highly targeted agents have led regulatory authorities to 
approve a majority of them on an expedited or priority basis, often on limited preliminary data indicative 
of their safety, efficacy and a favourable risk/benefit ratio [1-3]. Often, such approvals are associated with 
requirements for appropriate post-approval studies to substantiate these early expectations. 
As of 31 May 2016, 27 such agents have been approved by the US Food and Drug Administration (FDA) 
for use in oncology indications, beginning with the first approval of imatinib in May 2001. Two additional 
PKIs have also been approved by the FDA but for non-oncology indications – tofacitinib and nintedanib for 
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the treatments of rheumatoid arthritis and of idiopathic pulmonary fibrosis, respectively. In the European 
Union (EU), however, nintedanib is also approved for non-small cell lung cancer and at the time of writing, 
one of the 29 agents (alectinib) approved by the FDA was still under review, whereas tofacitinib had been 
rejected for approval, by the European Medicines Agency (EMA).  
In addition to the development of new PKIs, the agents already approved for one cancer are also being 
tested for their potential therapeutic benefits in other cancers and the range of oncology indications for 
many of these previously approved agents is gradually expanding [4-7]. For example, imatinib, initially 
approved for use in chronic myeloid leukaemia, now enjoys no less than seven distinct indications. The 
approval dates and the broad cancer-specific indications of the agents approved by the FDA and/or the 
EMA are shown in Table 1.  
Unfortunately, PKIs are also associated with a number of adverse side effects, many potentially fatal, on 
cardiovascular system (e.g. QT interval prolongation of the surface electrocardiogram (ECG), hypertension, 
left ventricular (LV) dysfunction, arterial thrombotic events (ATEs), venous thrombo-embolic events, 
bleeding and symptomatic bradycardia) and non-cardiovascular systems (such as hepatic, pulmonary, 
dermatological thyroid, ocular and renal) [8]. Many of these adverse effects are on-target effects which 
correlate with efficacy and therefore, difficult to avoid without compromising therapeutic benefit by 
simple dose reductions [8-17]. It is beyond the scope of this review to discuss the full safety profile of PKIs 
and the interested reader is referred to other reviews [2, 3, 18-39]. Despite this constellation of side effects 
associated with PKIs, the one that has engendered a phobia, often leading to early termination from 
further development, is the potential of a PKI to prolong the QTc interval. In rare cases, prolonged QT 
interval may predispose the patient to potentially fatal ventricular tachyarrhythmias. The FDA guidance on 
pre-marketing risk evaluation and assessment recommends the sponsor to address, as a part of the new 
drug application (NDA) for all new small molecule drugs, their potential for six serious adverse effects, one 
of them being drug-related QTc prolongation [40]. The others are drug-related liver toxicity, 
nephrotoxicity, myelotoxicity, interactions with other drugs and polymorphic drug metabolism. 
This review aims to put in perspective the “QT-phobia” that surrounds the development of PKIs by 
highlighting just two of their other more serious and relatively more frequent cardiovascular effects, 
namely LV dysfunction and ATEs. It will focus on 28 oncology-related PKIs including nintedanib which 
enjoys an oncological indication in the EU. For the purpose of this review, these 28 PKIs approved during 
the last 15-years since 2001 are divided into two groups with reference to the dates of their first approval 
by the US FDA. The dates selected are the FDA approval date because typically, the FDA is also the 
authority that has led the way in first approvals of each agent [1]. One group includes 16 (57 %) agents 
approved over 11.5 years from May 2001 to September 2012 (henceforth referred to as Period 1) and the 
other includes 12 (43 %) agents approved more recently during the last 3.7 years from October 2012 to 
May 2016 (Period 2). The pace of development of these agents is self-evident; 1.39 agents per year in 
period 1 and 3.24 agents per year in period 2. The labels of approved PKIs continue to evolve as more data 
become available and therefore, the information reviewed herein is sourced from a variety of documents 
referred to in earlier reviews [1-3], the most current updated labels and the author’s overall assessment of 
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Broad-term indication(s) (for use in selected patients 
with) 
Afatinib 12 July 2013 25 Sept. 2013 Non-small cell lung cancer 
Alectinib 11 Dec. 2015 UNDER REVIEW Non-small cell lung cancer 
Axitinib 27 January 2012 13 Sept. 2012 Renal cell carcinoma 
Bosutinib 4 Sept. 2012 27 March 2013 CML 
Cabozantinib 29 Nov. 2012 21 March 2014 Thyroid cancer, Renal cell carcinoma 
Ceritinib 29 April 2014 6 May 2015 Non-small cell lung cancer 
Cobimetinib 10 Nov. 2015 20 Nov. 2015 Melanoma 
Crizotinib 26 August 2011 23 Oct. 2012 Non-small cell lung cancer 
Dabrafenib 29 May 2013 26 August 2013 Melanoma 
Dasatinib 28 June 2006 20 Nov. 2006 CML, ALL 
Erlotinib 18 Nov. 2004 19 Sept. 2005 Non-small cell lung cancer, Pancreatic cancer 
Gefitinib 5 May 2003 20 June 2009 Non-small cell lung cancer 
Ibrutinib 13 Nov. 2013 21 Oct. 2014 
Mantle cell lymphoma, CLL, Waldenström’s 
macroglobulinaemia 
Imatinib 10 May 2001 11 Nov. 2001 




Lapatinib 13 March 2007 10 June 2008 Breast cancer 
Lenvatinib 13 February 2015 28 May 2015 Thyroid cancer 
Nilotinib 29 October 2007 19 Nov. 2007 CML 
Nintedanib 
17 October 2014 
(Not applicable) 
15 Jan. 2015 
21 Nov. 2014 
Idiopathic pulmonary fibrosis 
Non-small cell lung cancer 
Osimertinib 13 Nov. 2015 2 Feb. 2016 Non-small cell lung cancer 
Pazopanib 19 October 2009 14 June 2010 Renal cell carcinoma, Soft tissue sarcoma 
Ponatinib 14 Dec. 2012 1 July 2013 CML, ALL 
Regorafeniib 27 Sept. 2012 26 August 2013 Colorectal cancer, GIST 
Ruxolitinib 16 Nov. 2011 23 August 2012 Myelofibrosis, Polycythaemia vera rubra 
Sorafenib 20 Dec. 2005 19 July 2006 
Hepatocellular carcinoma, Renal cell carcinoma, Thyroid 
cancer 
Sunitinib 26 January 2006 19 July 2006 
Renal cell carcinoma, GIST, Pancreatic neuroendocrine 
tumour 
Trametinib 29 May 2013 30 June 2014 Melanoma 
Vandetanib 6 April 2011 17 Feb. 2012 Thyroid cancer 
Vemurafenib 17 August 2011 17 Feb. 2012 Melanoma 
Tofacitinib 6 November 2012 
REFUSED on 
26 April 2013 Rheumatoid arthritis 
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Background to QT-phobia 
The QT interval measured on the ECG varies with the heart rate and therefore requires correction to 
compute a heart rate-corrected QT interval (QTc interval) to determine the effect of an intervention. The 
correction formula most widely used for regulatory submissions and safety assessment is the Fridericia, 
study population-specific or individual subject-specific correction formula to compute QTcF, QTcP or QTcI 
interval, respectively. QTc interval prolongation per se is not harmful. However, at the level of an individual 
patient, prolonged QTc interval, when excessive (typically significantly greater than 500 ms) and/or in 
presence of certain risk factors, induces a potentially fatal form of ventricular tachyarrhythmia, known as 
torsade de pointes (TdP) [41,42]. Although typically of short duration, asymptomatic and self-terminating, 
TdP is infrequently sustained and symptomatic in a small proportion of cases and in 20 % or so of these 
patients, it degenerates into ventricular fibrillation, leading to death [43,44]. Historically, this 
proarrhythmia (or the potential thereof) has been responsible for about a third of the drug withdrawals 
from the market [45, 46]. The approval of many others has been either delayed or associated with 
prescribing restrictions in terms of narrow indication(s), contraindications and/or warnings and monitoring 
precautions [47].  
Arising from this historical experience with a large number of drugs across a wide range of 
pharmacological and therapeutic classes including oncology, the potential of new drugs to prolong the QTc 
interval and induce TdP is one principal safety issue that has continued to worry the regulatory authorities 
over the last two decades, although QTc interval prolongation per se does not correlate well with 
torsadogenic potential. This imperfect correlation between QT prolongation and risk of TDP is explained by 
the fact that whereas QT prolongation results from blockade of human ether-a-go-go (hERG) channel and 
prolongation of action potential duration (APD), TdP is a triggered activity arising from early after-
depolarizations (EADS) and the risk of EADs followed by TdP is modulated by other ancillary properties of 
the drug, such as blockade of calcium or late sodium currents or autonomic receptors [48-51]. Ranolazine 
(an antianginal drug) and sertindole (a neuroleptic agent) best illustrate the role of late sodium current and 
α-blocking activities, respectively, in modulating the risk of TdP following QT interval prolongation [52-56]. 
In essence, therefore, TdP and fatality following drug-induced QTc prolongation are events that are much 
rarer than would be anticipated. For example, Laksman et al. [57] have reported that, among 172 in-
hospital patients with QTc interval > 550 ms, in-hospital mortality was 29 %, with only 4 % of patients 
experiencing arrhythmic deaths, all of which were attributed to secondary causes. 
In a vast majority of cases, drug-induced prolongation of the QTc interval results from delayed 
ventricular repolarization due to inhibition of the (major) outward repolarizing potassium current mediated 
by hERG subunit of the rapid component of the delayed rectifier channel (IKr) [58]. Non-antiarrhythmic 
drugs can be characterised for this off-target undesirable pharmacological property in nonclinical in vitro 
and in vivo studies as well as clinical in vivo studies. Not surprisingly, therefore, regulatory authorities have 
reacted to this potential by promulgating guidelines for pre-approval characterisation of all new drugs with 
systemic bioavailability for their “QT-liability” [47, 59-62]. This is the only adverse drug effect that has 
called for specifically targeted and internationally harmonised detailed guidelines [60, 61]. Clinically, this 
QT-liability is determined in a formal and dedicated study, referred to as the thorough QT (TQT) study, that 
includes two dose levels of the investigational drug, a placebo and an active control. In order to avoid any 
false negatives and as a matter of precaution, the threshold of regulatory concern for a maximum mean 
increase in QTc interval from baseline in the TQT study has been (arbitrarily) set low at around 5 ms as 
evidenced by an upper bound of the 95 % confidence interval (CI) around the mean effect on QTc of 10 ms 
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[61]. However, QTc prolongation is an imperfect surrogate of torsadogenesis and therefore, it is 
acknowledged by all concerned (including the regulatory authorities) that a drug endowed with QT-liability 
does not necessarily mean that the drug is proarrhythmic; a breach of the above regulatory threshold 
simply calls for more diligent and intensive ECG monitoring in subsequent clinical trials. Nevertheless, the 
sponsors have frequently reacted by terminating further development of new agents, often on the basis of 
an early in vitro hERG study or first-in-human study, because of the fears and regulatory uncertainties 
surrounding the possible finding of a modest but often clinically irrelevant breach of the regulatory 
threshold by the drug concerned in what is a cost-ineffective and resource-intensive TQT study. 
QTc-liability of protein kinase inhibitors 
Overall, as shown in Table 2, 11 (39 %) of the 28 PKIs have the potential to prolong the QTc interval to a 
variable extent. These 11 agents are considered to have the QT-liability on the basis that their QTc effect 
had breached the above very conservative threshold of regulatory concern; as a result, the labels of two 
(nilotinib and vandetanib) carry a black box warning. Interestingly, QTc-liability is reported for eight (50 %) 
of the 16 agents approved in period 1 in contrast to only 3 (25 %) of the 12 approved in period 2, possibly 
suggesting early termination of PKIs from development during period 2 due to this pharmacological 
property. 
However, experience with QTc-prolonging drugs that are known to be torsadogenic and non-
torsadogenic has shown that drugs associated with maximum mean placebo-corrected increases of 6-10 
ms are unlikely to be torsadogenic whereas drugs associated with increases of 16-20 ms are probably 
torsadogenic [63]. Lin and Kung have also summarized data which suggest that a mean QTc increase of 
19.3 ms associated with strong torsadogens is significantly greater than the 8.0 ms for borderline 
torsadogens [64]. 
By comparison with known non-PKI torsadogens, the QTc effect of majority of the PKIs that prolong the 
QTc interval (often determined at supratherapeutic doses) appears to be relatively mild/modest with a 
maximum mean effect of around 10 ms (95 % upper bound around their mean effects being around 15 
ms). Six PKIs (osimertinib, ceritinib, sunitinib, lapatinib, nilotinib and vandetanib) appear to have somewhat 
larger effects with a maximum mean effect ranging from 13.5 to 34.7 ms (95 % upper bound around the 
mean effect being 17.6, 22.2, 22.4, 23.4, 25.8 and 36.4 ms respectively) [2,3]. However, since some of 
these effects are not placebo-corrected, the true extent of the drug’s QTc-prolonging effect remains 
uncertain. Therefore, it is interesting to note that the number of patients receiving any of these PKIs who 
developed a QTc interval prolongation > 500 ms is typically well below 0.5 % except lapatinib (6 %) and 
vandetanib (4.3 %) [2]. In pre-approval clinical trials, only pazopanib and vandetanib were each associated 
with two cases of TdP, although the causal association with pazopanib in one case appeared uncertain 
since the patient was also receiving amiodarone [2]. In a dedicated QT study as required by the regulatory 
guidance, the maximum mean increase in baseline-adjusted, time-matched QTcF interval in pazopanib-
treated patients versus placebo was only 4.4 ms (95 % upper bound 11.2 ms) [65]. Mixed-effects modelling 
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Period 1 (May 2001 – September 2012) 
Number of PKIs approved = 16 
Period 2 (October 2012 – May 2016) 















Afatinib **         
Alectinib **         
Axitinib *          
Bosutinib *         
Cabozantinib**         
Ceritinib **         
Cobimetinib**         
Crizotinib *          
Dabrafenib **          
Dasatinib *         
Erlotinib *         
Gefitinib *         
Ibrutinib **         
Imatinib *           
Lapatinib *           
Lenvatinib **         
Nilotinib *            
Nintedanib **         
Osimertinib **         
Pazopanib *           
Ponatinib **           
Regorafeniib *          
Ruxolitinib *         
Sorafenib *          
Sunitinib *            
Trametinib **         
Vandetanib *          
Vemurafenib *         
PKIs with the 
effect 50 % 75 % 63 % 63 % 25 % 58 % 58 % 33 % 
* PKI approved in Period 1; ** PKI approved in Period 2;  With black box warning;  Post-approval addition or revision 
The rarity of QT-related proarrhythmia risk of PKIs is further corroborated by post-marketing data. 
During the post-marketing use of 16 PKIs approved in period 1 and for which some data are available, 
there were a total of 463 reports of QT interval prolongation but only 20 reports of TdP; only vandetanib 
was associated with significant risk of TdP [3]. Spontaneous reporting data must of course be interpreted 
with great caution but although crizotinib, dasatinib, vandetanib and nilotinib were associated with 14, 35, 
57 and 246 reports of QTc interval prolongation during their post-marketing use, the corresponding 
number of reports of TdP were only 0, 1, 2 and 3, respectively, thus further emphasising that not all events 
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of QT interval prolongations degenerate into TdP and the rarity of this potentially fatal proarrhythmia. 
Although there were a total of 220 reports of sudden death, there was similar discordance between the 
QT-liability of a drug and the number of reports of sudden death associated with it. Kloth et al. [66] have 
also reported a post-marketing observational study of 363 patients who were eligible for the analyses of 
QTc interval before and during treatment with erlotinib, gefitinib, imatinib, lapatinib, pazopanib, sorafenib, 
sunitinib or vemurafenib. The median on-treatment time before the ECG was performed was 43 days. 
Mean (range) QTc intervals were 401 (388–415) ms at baseline and 415 (397–431) ms following therapy. A 
total of 33 patients (9.1 %) were characterised by an increased grade of Common Terminology Criteria for 
Adverse Events (CTCAE). Only two individuals passed from grade 1 to grade 2 or 3 and nine patients (2.5 %) 
had a decrease in their CTCAE grade for QTc interval. However, 321 (88.4 %) patients did not have a change 
in their CTCAE grade after the start of PKI treatment. Only five patients (1.4 %) developed QTc  500 ms 
after starting the therapy, with all of them experiencing an increase of 100 ms from baseline. Despite this 
marked increase from baseline, none was reported to have a proarrhythmia.  
One potential explanation for the above discordance, also observed all too often with drugs in other 
pharmacological or therapeutic classes, is that the PKIs concerned may have a risk-mitigating inhibitory 
effect on other ion currents involved in APD, such as the calcium and/or late sodium currents as explained 
earlier [48-51]. Whether or not PKIs generally inhibit these ion channels is at present unclear since they are 
not routinely studied for these effects. Protein kinases activate downstream signalling via phosphoinositide 
3-kinase (PI3K). The complexity of the interactions is demonstrated by one study reporting that chronic but 
not acute exposure to nilotinib prolonged the APD in canine cardiomyocytes, an effect which was reversed 
by intracellular dialysis with phosphatidylinositol 3,4,5-trisphosphate (which is a downstream effector of 
PI3K) [67, 68]. These investigators also observed that APD prolongation by nilotinib was mediated by 
decreases in both the rapid (IKr) and slow (IKs) components of the delayed rectifier potassium current, as 
well as by an increase in late sodium current (an effect which in theory ought to aggravate the 
proarrhythmia risk [69]); however, nilotinib also reduced the calcium current.   
One obvious and hitherto unquantified by-product of the “QT-phobia” is that many new candidate 
compounds are abandoned very early in their development without fully exploring their potential for 
significant therapeutic benefit. The unfortunate reality, however, is that the “QT-liability” of a drug is only 
an imperfect predictor of the proarrhythmia risk, and just one component of its much wider cardiovascular 
and overall safety. Of equal concern with regard to determining the duration of QTc interval in routine 
clinical practice is the fact that the QTc interval value depends on the correction formula applied to the 
measured QT interval. The most common formula applied in routine clinical practice is the Bazett’s formula 
(that computes QTcB interval) which has been shown to be highly imprecise when there are significant 
changes in heart rate [70-73]. Although regulatory documents and drug labels provide guidance on dose 
adjustment in patients who develop, or are at risk of developing QTc prolongation, they provide no 
guidance on the formula to be used. Similarly, the US National Cancer Institute, which has recently 
modified the criteria for QTc interval in the latest version of CTCAE (v4.03) [74], provides no guidance on 
the choice of a formula for computing QTc interval duration. 
It is therefore timely to contrast and put in perspective the foregoing rarity of adverse clinical outcomes 
from PKI-related effects on QTc interval with their effects on two specific cardiovascular effects, LV 
dysfunction and ATEs, which are of much greater concern and have a significant direct impact on 
morbidity, mortality and risk/benefit. 
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Left Ventricular Dysfunction due to Protein Kinase Inhibitors 
Left ventricular (LV) dysfunction is now a well-recognised toxicity of a number of PKIs. It can range from 
asymptomatic ECG changes (in QRS and T-waves and ST-segment) through decrease in LV function 
(detectable noninvasively only by echocardiography or radionuclide techniques) to clinically manifest 
severe congestive heart failure (CHF) and generalised fluid retention [75-77]. Although not precisely known 
or understood, the potential mechanism underpinning this effect has been reviewed previously by others 
[2, 78-81].  
Post-approval, the US labels of a number of PKIs have been revised well after their initial approval to 
include new warnings and precautions regarding the risks of LV dysfunction and/or fluid retention. These 
are axitinib, dabrafenib, imatinib, nilotinib and pazopanib, although there are some question marks 
concerning the potential of imatinib to induce cardiac dysfunction. During its post-marketing use as of 25 
February 2015, about 14,700 patients worldwide had received crizotinib since its approval [82]. Forty cases 
of cardiac failure had been reported in the post-marketing setting. A review by European medicines 
regulators of data from clinical trials and reports from clinical practice concluded that this side effect is 
common, occurring in 1-10 % of the patients taking crizotinib [82]. In most cases, cardiac failure occurred 
within one month of starting the treatment and affected patients with or without pre-existing cardiac 
disorders. The reports included cases where the evidence of symptoms of cardiac failure resolved after 
stopping crizotinib and recurred when it was reintroduced. Some cases had a fatal outcome.  It is 
noteworthy that in contrast to the revised European Union prescribing information, the most current FDA 
label of crizotinib (dated 29 April 2016) warns about symptomatic bradycardia but does not make any 
reference to cardiac failure [83]. 
Currently, 17 (60 %) of the 28 PKIs, approved as of 31 May 2016, are known to induce LV dysfunction, 
often loosely termed as “cardiomyopathy” or “cardiotoxicity”, and cardiac failure. It is evident that 10 (63 
%) were among the 16 approved in period 1 and 7 (58 %) among the 12 approved in period 2. This trend is 
in contrast to the substantial reduction in the number of QT-prolonging drugs approved during period 2 
compared to period 1 (from 50 % to 25 % for QTc-prolonging drugs versus from 63 % to 58 % for drugs 
affecting cardiac dysfunction). Not only that but also the total number of PKIs with an adverse effect on 
cardiac function (n=17; 60 %) is much higher than those with a QT-liability (n=11; 39 %). 
The complexity surrounding the estimation of incidence and interval to onset has been reviewed before 
since these depend on the dose of the drug and the criteria used to define LV dysfunction as well as 
previous chemotherapy. In broad terms, asymptomatic decrease in LV ejection fraction is by far the most 
frequent. However, overt CHF is not uncommon with an incidence as high as 5-8 % with sunitinib and 
pazopanib. A number of recent meta-analyses of clinical trials have quantified the risk of PKI-induced 
symptomatic cardiac failure [21,22,84]. These events are typically categorised as all- and high-grade (grade 
3 and higher) as defined by CTCAE. Grade 3 CHF events require intervention, and grade 4 CHF events 
usually include life-threatening dysfunction. These meta-analyses reveal that overall, the incidences of all-
grade and high-grade CHF are about 2.8 % and 1.1 %, respectively, with a relative risk (RR) of 2.5 and 1.5, 
respectively. The risk appears independent of tumour type or the PKI used. The outcome has been fatal in 
a number of cases whereas others require anti-failure therapy and/or withholding the culprit PKI. In 
routine clinical oncology, the scale of the problem is likely much higher as patients with cardiac disease 
who are the most at risk of cardiotoxicity have traditionally been excluded from pre-approval clinical trials. 
As stated above, four (23 %) of the 17 PKIs with a potential for inducing cardiac failure revealed this risk 
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during their post-marketing use. Currently, there are no regulatory guidelines for pre-approval 
characterisation of a drug for its effect on LV function. However, as Yang and Papoian from the FDA point 
out, these reports of cardiac toxicity following the clinical use of PKIs are unexpected and not well 
predicted by nonclinical studies [85] and clinical findings have exposed gaps in current nonclinical drug 
testing for predicting the development of cardiac toxicities in humans. They have suggested the use of 
cultured cardiomyocytes and application of isolated perfused heart methodology to chronic or sub-chronic 
rodent studies or including echocardiography in chronic large animal toxicity studies as potentially valuable 
tools to study the likelihood of PKI-mediated cardiotoxicity. Available data suggest that nonclinical studies, 
when adequately designed to address a specific issue, are capable of detecting these effects as was seen in 
studies with some PKIs approved more recently. For example, in vivo cardiac safety pharmacology studies 
with osimertinib did suggest equivocal findings of decreased contractility dogs and guinea pigs whereas 
increased findings of cardiomyopathy compared to findings in control animals were reported in the 4-week 
rat toxicology study with cobimetinib though no other cardiac effects were reported in animal studies [86, 
87]. With regard to afatinib, a decrease in left ventricular function was noted at a dose of 30 mg/kg in a 
single continuous intravenous administration study in domestic pigs [88]. Use of echocardiography 
unequivocally identified sunitinib-induced cardiac LV dysfunction but failed to detect an effect of bosutinib 
[89, 90]. Although electrocardiography is widely used to study QTc effects, echocardiography has not been 
used as frequently to study LV function in nonclinical studies. There clearly lies a significant challenge in 
pre-approval characterisation of a drug for its effect on LV function. Recent studies have shown that a 
multi-parameter approach examining both cardiac cell health and function in human induced pluripotent 
stem cell-derived cardiomyocytes provides a comprehensive and robust assessment that can aid in 
determining potential cardiotoxic liability [91].  
Arterial thrombotic events due to protein kinase inhibitors 
Among the most serious adverse effects of the PKIs are their prothrombotic effects as illustrated by 
ponatinib [reviewed in 3]. Following the post-marketing experience with ponatinib (see below), ATEs have 
now emerged as a major safety concern with PKIs and the previously approved labels of a few have 
required revisions to reflect this risk. 
Ten (63 %) of the 16 PKIs approved during period 1 have been reported to be associated with arterial 
thrombosis (axitinib, dasatinib, erlotinib, imatinib, nilotinib, pazopanib, regorafenib, sorafenib, sunitinib 
and vandetanib). Among the 12 newer PKIs approved in period 2, four (33 %) have been reported to be 
associated with ATEs (cabozantinib, lenvatinib, nintedanib, and ponatinib, with the last one carrying a black 
box warning) [3]. The rates of ATEs appear to be comparable for PKIs from both periods and the ATE events 
typically include cerebral infarction, cerebral ischaemia, cerebrovascular accidents (CVA), myocardial 
infarction and myocardial ischaemia. In pre-approval clinical trials, the incidences of ATEs were 5 % with 
lenvatinib, 2.5 % for nintedanib and 2 % for cabozantinib, the corresponding placebo rates being 2 %, 0.8 % 
and 0 % respectively. Thus, the mean drug-emergent effect was of the order of 2.2%. Myocardial infarction 
was the most common adverse reaction, occurring in 1.5 % of nintedanib-treated patients compared with 
0.4 % of placebo-treated patients. The incidence of grade 3 or higher events was 3 % in lenvatinib-treated 
patients compared with 1 % in the placebo group.  
One meta-analysis involving 10,255 patients receiving sunitinib and sorafenib revealed an incidence of 
ATEs to be 1.4 % (95 % CI: 1.2–1.6) [23]. Another meta-analysis involving a total of 9,711 patients from 19 
trials concluded that the overall incidence of ATEs was 1.5 % (95 % CI: 1.0–2.3) following the use of VEGFR 
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PKIs [24]. The most common ATEs were myocardial ischaemia/infarction (67.4 %), central nervous system 
ischaemia (7.9 %) and CVA (6.7 %). The odds ratio (OR) was significantly increased when compared with 
controls (OR 2.26, 95 % CI: 1.38–3.68; p = 0.001) and this did not vary significantly with tumour types (p = 
0.70), VEGFR PKIs (p = 0.32), treatment regimens (p = 0.76), phase of trials (p = 0.37) and sample size (p = 
0.89). Thus, the overall incidence of ATEs with VEGFR inhibitors is about 1.50 % with an RR in the region of 
2.6. Available limited evidence suggests that EGFR inhibitors may not be associated with this risk.  
In a post-marketing observational study by Srikanthan et al. [92], three agents were studied: erlotinib, 
sorafenib and sunitinib. Patients treated with these agents were compared to 128,415 age and gender 
matched individuals without cancer who served as controls. Of the 1,642 PKI-treated patients followed up, 
1.1 % developed a myocardial ischaemic event requiring hospitalization, 0.7 % developed a CVA requiring 
hospitalization and 1,184 (72.1 %) died. 61 % of the myocardial ischaemic event events and 73 % of the 
CVA events were associated with erlotinib, and these proportions closely mirrored the relative frequency 
of drug use in the population. Cardiovascular events predominantly occurred late in follow-up. When 
patients with and without baseline ischaemic heart disease were compared, 3.3 % versus 0.5 %, 
respectively, developed a myocardial ischaemic event and 1.2 % versus 0.5 %, respectively, developed CVA. 
However, the mortality rates were no different (72.5 % vs. 72.0 %, respectively). These investigators 
summarised that individuals treated with PKIs have a significantly higher hazard of death relative to the 
general population but cause-specific hazards of ischaemic heart disease and cerebrovascular accidents are 
not increased. Jang et al. [93] have recently reported cardiovascular events in 171 (26 %) of the 670 
patients aged > 65 years treated with sunitinib or sorafenib. The incidence rates for CHF or 
cardiomyopathy, acute myocardial infarction and stroke were 0.87, 0.14, and 0.14 per 1000 person-days, 
respectively. The use of either agent was associated with an increased risk of cardiovascular events (hazard 
ratio (HR) 1.38; 95 % CI: 1.02-1.87) and stroke (HR 2.84; 95 % CI: 1.52-5.31) in comparison with 788 
patients diagnosed with advanced renal cell carcinoma who did not receive either agent. 
Case of ponatinib 
When first approved in December 2012, ponatinib was already strongly associated with cardiovascular, 
cerebrovascular, and peripheral vascular thrombosis, including fatal myocardial infarctions and strokes 
[94]. Overall, fifty-one (11 %) of the 449 patients experienced an arterial thrombotic event of any grade. 
Myocardial infarction or worsening coronary artery disease was the most common event which occurred in 
21 patients (5 %) of ponatinib-treated patients. The range of events included congestive heart failure 
(concurrent or subsequent to the myocardial ischaemia), cerebrovascular events, hemorrhagic conversion 
of the initial ischemic event, stenosis of large arterial vessels of the brain and peripheral arterial events 
with digital or distal extremity necrosis. Serious arterial thrombosis occurred in 34 (8 %) of the 449 of 
ponatinib-treated patients, as a consequence of which 21 patients required various revascularization 
procedures. Thirty of these 34 patients had one or more of the well recognised cardiovascular risk factors. 
Patients with cardiovascular risk factors appeared to be at increased risk for arterial thrombosis following 
treatment with ponatinib. As a condition of approval, the FDA had required the sponsor to characterize the 
safety of ponatinib and submit long-term safety data over a follow-up period of at least 12 months from all 
ongoing patients in a specific randomized controlled trial (referred to as AP24534-12-301) that adequately 
isolated the effect of the drug [95].  
However, just over 10 months later as of 31 October 2013, approximately 24 % of patients in one phase 
II clinical trial (median treatment duration 1.3 years) and approximately 48 % of patients in a phase I clinical 
trial (median treatment duration 2.7 years) had experienced serious adverse vascular events [96]. A 
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number of these patients required urgent surgical procedures to restore blood flow. In some patients, fatal 
and serious adverse events occurred as early as 2 weeks after starting ponatinib therapy. 
Since a safe dose or duration of exposure could not be identified, the sponsor agreed to the request 
from the FDA to suspend marketing and sales of ponatinib [96]. Following a thorough assessment of all 
available data, the FDA on 20 December 2013 required several new safety measures to be implemented, 
including restricted indication and additional warnings and precautions, before resumption of marketing to 
appropriate patients [97]. The FDA also required a risk evaluation and mitigation strategy (REMS) and the 
sponsor to conduct post-marketing investigations to further characterise the dose and the safety of the 
drug. 
The most current label for ponatinib, dated 2 June 2016 [98], includes a more detailed account of 
vascular occlusion with age-related increase in incidence (18 %, 33 % and 56 % for those aged  49, 50-74 
and  75 years, respectively and prior history of risk factors and 12 %, 18 % and 46 % respectively for those 
without prior risk factors. The overall incidence is computed to be 24 % for vascular occlusion and 20 % for 
arterial thrombosis and occlusion. It was also found to cause renal artery stenosis, associated with 
worsening, labile or treatment-resistant hypertension in some patients. However, the dose that was 
approved initially has remained unchanged over time at 45mg once daily [94, 98].  
Leaving aside the rather atypical example of ponatinib, it is still sufficiently evident that PKI-induced 
ATEs, rather than their QT-liability, have a far greater impact on quality of life, morbidity and mortality of 
patients receiving PKI therapy. 
Protein kinase inhibitors and fatalities due to non-QT related cardiovascular adverse events 
From the foregoing, it is not surprising that non-QT related cardiovascular effects feature heavily in 
various studies of fatal adverse events (FAE) associated with PKIs, especially those agents that target 
angiogenesis (VEGFR inhibitors).  
VEGFR inhibitors 
Three large and independent meta-analyses [99-101], summarised in Table 3, involving 12,870 patients 
receiving VEGFR inhibiting PKI and 11,114 control patients have quantified the incidence of FAE to be in the 
range of 1.50-2.26 % with a RR in the range of 1.64-2.23. The PKIs studied were sunitinib, sorafenib, 
pazopanib, vandetanib, axitinib, cabozantinib, lapatinib and regorafenib. Adverse effects such as cardiac 
failure, myocardial infarction, stroke, thrombo-embolism, haemorrhage and cardiopulmonary insufficiency 
feature prominently in the list of these FAEs. Other often reported events included hepatic failure, 
respiratory events, intestinal perforation and renal failure as well as sudden death. Yang et al. [102] have 
recently reported that patients treated with sorafenib had a significantly greater risk of mortality than 
those in placebo/control groups, with an RR of 1.75. Among different VEGFR-PKIs, sorafenib and sunitinib 
were associated with a significant risk of death when compared with control arms, respectively. 
Combination of VEGFR-PKIs with other antineoplastic agents, but not VEGFR-PKI monotherapy, significantly 
increased the risk of treatment-related deaths.  
Subgroup analyses have revealed some interesting results. Whereas Schutz et al. [100] reported no 
difference in the rate of FAEs found between different VEGFR PKIs or tumour types, Hong et al. [101] 
reported a significantly increased risk of death in patients with non-small cell lung cancer and colorectal 
cancer. This indication-related increased risk of death following treatment with sorafenib has also been 
reported by Yang et al. [102] who found an overall incidence of sorafenib-associated mortality to be 3.3 % 
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but patients with renal cell carcinoma and thyroid cancer had treatment-related mortality ≥5 %. Recently, 
Jean et al. [103] have also reported a distinct increase in the rate of occurrence of adverse effects of 
sorafenib when used in differentiated thyroid cancer compared with renal and hepatocellular cancer. 
While many theoretical explanations have been advanced to explain this indication-related difference in 
toxicity profile, the exact mechanism for this remains unclear. 
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In contrast to VEGFR-PKIs, Qi et al. [104] reported a meta-analysis of 7,508 patients treated with two 
widely used EGFR-PKIs (erlotinib and gefitinib) and compared them with 6,317 control patients to 
determine the incidence and risk of FAEs. The overall incidence of FAEs was 1.9 % (95 % CI: 1.2 - 2.9), and 
the RR was 0.99 (95 % CI: 0.70 - 1.41; p = 0.97). No increase in FAEs was detected in any pre-specified 
subgroup. This analysis suggests that the use of EGFR-PKIs does not increase the risk of FAEs in patients 
with advanced solid tumours, and EGFR-PKIs are safe and tolerable by cancer patients, especially for those 
previously treated patients. In the context of this finding, it is worth noting that typical EGFR-PKIs are not 
known to induce cardiovascular adverse events that are so typical of VEGFR-PKIs, thus emphasising the 
impact of these events on the risk/benefit of PKIs. 
PKI in combination with cytotoxic agents 
In a more comprehensive meta-analysis of 43 trials involving 16,011 patients (8,460 on PKIs and 7,551 
controls) that balanced the risks versus the benefits of PKIs active at VEGFR and EGFR, Funakoshi et al. 
[105] evaluated the safety and efficacy of combining cytotoxic chemotherapy with PKIs, which were 
divided into two subgroups: VEGFR PKI (axitinib, cabozantinib, pazopanib, regorafenib, sorafenib, sunitinib 
and vandetanib), and EGFR-family PKI (erlotinib, gefitinib and lapatinib). They found that compared with 
chemotherapy alone, the addition of a PKI was associated with a significant improvement in progression 
free survival (hazard ratio 0.82; 9 5% CI: 0.76–0.89), but not overall survival (hazard ratio 0.99; 95 % CI: 
0.95–1.03). However, the addition of a PKI significantly increased the risk of FAEs (RR = 1.63, 95 % CI: 1.32–
2.01), treatment discontinuation (RR = 1.80, 95 % CI: 1.58–2.06), and any severe adverse event (RR = 1.25, 
95 % CI: 1.16–1.36). Surprisingly, the RR associated with addition of a PKI was 1.49 (95 % CI: 1.16-1.90) with 
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VEGFR inhibitors compared to 2.04 (95 % CI: 1.38-3.01) with EGFR inhibitors. These findings serve to 
caution the physicians to weigh the risk of toxicity versus the modest benefit in terms of progression free 
survival associated with chemotherapy plus a PKI in patients with solid cancers.   
Safety of protein kinase inhibitors in routine clinical practice 
In routine clinical practice, however, the risk/benefit is likely to be inferior to that determined from 
highly controlled clinical trials. Whereas patients in pre-approval clinical trials are carefully selected, 
treatment of wider and less selected patient population in routine oncologic practice may increase the 
likelihood of toxicity and lower the probability of benefit [106]. The problem may be further compounded 
by off-label use of oncology drugs. One study from Switzerland reported a total of 985 consecutive patients 
receiving 1,737 anticancer drug treatments and found that overall, 32.4 % of all patients received at least 
one off-label drug, corresponding to 27.2 % of all anticancer drugs administered [107]. 
Following a detailed analysis of the adverse drug reactions of targeted anticancer agents from their 
reporting in pivotal randomized clinical trials and subsequently updated drug labels, Seruga et al. [108] 
concluded that many rare but serious and potentially fatal adverse drug reactions associated with these 
agents are not reported in clinical trials. One study on cancer drugs in Japan reported that of the 111 fatal 
adverse drug reactions detected in the eight post-marketing surveillances, only 28 (25.0 %) and 22 (19.6 %) 
were described on the initial global and the initial Japanese drug label, respectively, and 58 (52.3 %) fatal 
adverse drug reactions were first described in the all-case post-marketing surveillance reports [109].  
hERG blockade in oncology – a friend or a foe? 
Most of the 14 drugs withdrawn from the market due to their QT-related proarrhythmic proclivity were 
either old drugs with more effective newer alternatives or were indicated for relatively benign indications. 
As a result, their risk/benefit was considered unfavourable and it was prudent to have withdrawn them 
form the market. However, for the PKIs, the risk/benefit components are different. Not only are they 
indicated for life-threatening conditions with potentially no alternatives but also, their post-marketing 
performance suggests that the risk of QT-related proarrhythmia may have been over-estimated. Critically, 
as explained earlier, the risk assessment is based on a parameter (QT prolongation) that is known to be a 
poor predictor of the risk. If PKIs can be approved and continue to be marketed and used clinically despite 
clinically the most relevant risks of LV dysfunction and arterial thrombotic events, there seems no reason 
why they should be abandoned early during the course of their development because of the phobia about 
QT-related over-estimated risks of proarrhythmias.  
Since both ICH S7B and ICH E14 are principally “hERG-centric” and “QT-centric”, respectively, a new 
paradigm, referred to as the Comprehensive In vitro Proarrhythmia Assay (CiPA), is now gathering 
momentum among all the stake holders, including the regulatory authorities [110]. This paradigm, aiming 
to characterise the risk of proarrhythmias as opposed to QTc prolongation, recognises the critical role of 
multiple ion channels blockade and among other recommendations, calls for all new drugs to be studied 
for their effects on multiple ion channels and incorporation of these effects in an in silico computer 
modelling of human ventricular electrophysiology to predict a drug’s proarrhythmic potential.  
Of greater concern is the real possibility that discarding a PKI because it inhibits hERG channel may 
prove to be counter-productive since hERG is expressed in a variety of malignancies [111-113]. Early 
indications are that hERG channel blockers attenuate the progression of both hematologic malignancies 
and solid tumours [114-119]. Not surprisingly, hERG channel has been suggested as a potential target for 
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anticancer drugs [112, 120]. Among the interesting such drugs is astemizole, withdrawn from the market in 
1999 for its torsadogenic potential [46], which is not only a hERG blocker but also an antihistamine [121] 
and histamine favours proliferation of normal and cancerous cells. If hERG channel were to prove to be a 
valuable therapeutic target in oncology, new paradigms will have to evolve regarding the management of 
PKI-induced QT interval prolongation.  
Discussion and conclusions 
In contrast to their QT-liability, the hepatotoxic potential of PKIs is far greater. Nineteen (68 %) of the 
28 PKIs are labelled as potentially hepatotoxic with five them carrying a black box warning (Table 2). 
Twelve (75 %) of the 16 PKIs approved in period 1 and 7 (58 %) of the 12 approved in period 2 are deemed 
to be hepatotoxic. Four of the 12 from period 1 and one of the 7 from period 2 carry black box warning 
(lapatinib, pazopanib, regorafenib and sunitinib, and ponatinib, respectively). Although the potential for 
clinically relevant hepatic injury is typically evaluated on the basis of the magnitude of increases in serum 
aspartate and alanine transaminases (AST and ALT), alkaline phosphatase (ALP) and bilirubin, the risk 
assessment and labelling are based on the number of cases that meet “Hy’s rule”. According to this rule, a 
significant risk of severe hepatotoxicity is associated with medications which cause hepatic injury 
(elevation in ALT) together with reduction in hepatic function (the synthesis and transportation of bilirubin) 
in absence of any evidence of biliary obstruction (e.g. elevation of ALP) or of other causes that can 
reasonably explain these elevations in ALT and bilirubin. Hy’s rule has been validated and confirmed in two 
large studies of drug-induced liver injury in which approximately 10 percent of subjects with 
hyperbilirubinaemia or jaundice died or needed liver transplant [122, 123]. Finding one Hy’s rule case in the 
clinical trial database is worrisome; finding two is considered highly predictive of the drug having the 
potential to cause severe drug-induced liver injury when given to a larger population [124]. In pre-approval 
clinical trials of relevant PKIs, there were cases that met Hy’s rule or fatal cases of hepatic failure. 
Attribution of the risk of clinically relevant hepatotoxicity has been justified by numerous post-marketing 
reports of PKI-induced hepatotoxicity that required revisions to the labelling of several PKIs. Interestingly, 
however, although bosutinib is labelled as potentially hepatotoxic, a post-approval observational study in 
which 248 patients received bosutinib for a median duration of 27.5 months revealed no cases in the 
bosutinib arm that led to hospitalization, were associated with permanent hepatic injury or liver-related 
deaths, or met Hy’s rule criteria [125]. 
Thus, although the risks of proarrhythmia and hepatotoxicity are both determined on the basis of 
surrogate markers, the assessment of hepatotoxicity is based on a combination of clinically relevant and 
validated endpoints. There are also significant challenges to evaluating QT- and transaminase-based clinical 
risk. Whereas QT prolongation does not correlate well with the risk of proarrhythmias for the reasons 
already explained earlier, diagnosing drug-induced liver injury can be difficult in presence of metastasis. 
Development of newer PKIs should proceed on the basis of assessment of clinically meaningful risks and 
therapeutic benefits in terms of morbidity, mortality and quality of life if potentially valuable agents are 
not to be discarded early in their development programme without exploring their clinically meaningful 
benefits. Safe and effective use of these valuable drugs requires close collaboration between the 
oncologists and their colleagues in other specialties such as the collaboration which has been forged by 
oncologists and cardiologists [3]. 
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